CELU (Celularity Inc.) stock: $0.76, $24.7M market cap, $0.6M cash, $24.1M EV, $50.1M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life.
Status note MLASC (maternal leukocyte and stromal cell) candidate. Filing cites 'encouraging clinical data in Phase 1 and Phase 2 studies' and says the company is selectively advancing programs with a focus on longevity applications. (Note: latest available filing is the 10-Q for the period ended 2025-09-30.)
CYNK-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic NK cells)
Partnerships Dragasac: exclusive distribution and manufacturing agreement covering CYNK-001 (clinical/investigational/near-term commercial products); Genting Innovation: distribution and manufacturing rights incl. CYNK-001
Indications
Aging and other non-oncology indications(Stage not disclosed)
Status note Unmodified natural killer cell therapy. Filing references unmodified NK cell clinical trials under a contingent consideration agreement with Anthrogenesis; current clinical phase not stated in the 10-Q excerpts.
PSC-100
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
PDA-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
PDA-002
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
pEXO-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
APPL-001
Stage not disclosed · ActiveModality: Cell therapy (placental-derived allogeneic)
Partnerships Dragasac: exclusive distribution and manufacturing; Genting Innovation: distribution and manufacturing rights
Indications
Regenerative indications(Stage not disclosed)
Status note Listed as a cell therapy product in clinical development/investigational/near-term commercial use; indication and stage not stated in the 10-Q excerpts.
Per-asset detail extracted from the 10-Q filed 2025-11-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.